Details of the Drug

General Information of Drug (ID: DM2ZGAN)

Drug Name
Mesoridazine
Synonyms
Calodal; Lidanar; Lidanil; Mesoridazina; Mesoridazinum; Serentil; Serentil Concentrate; Thioridazien thiomethyl sulfoxide; Thioridazine monosulfoxide analog; Thioridazine thiomethyl sulfoxide; TPS 23; Tps23; Lidanar (TN); Mesoridazina [INN-Spanish]; Mesoridazinum [INN-Latin]; NC-123; Serentil (TN); TPS-23; Mesoridazine (USAN/INN); Mesoridazine [USAN:BAN:INN]; T-2-SO; THD-2-SO; Thioridazine-2-sulfoxide; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-phenothiazine; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine; 10-(2-(1-Methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-10H-phenothiazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine; 10-[2(1-Methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)phenothiazine; 10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfinyl phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1], [2]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 386.6
Topological Polar Surface Area (xlogp) 4.5
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption
The drug is well absorbed from the gastrointestinal tract [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 24 - 48 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 10.8106 micromolar/kg/day [5]
Chemical Identifiers
Formula
C21H26N2OS2
IUPAC Name
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
Canonical SMILES
CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C
InChI
InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
InChIKey
SLVMESMUVMCQIY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4078
ChEBI ID
CHEBI:6780
CAS Number
5588-33-0
DrugBank ID
DB00933
TTD ID
D04AAN
INTEDE ID
DR1033

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Mesoridazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Mesoridazine and Quetiapine. Schizophrenia [6A20] [28]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Mesoridazine and Aripiprazole. Schizophrenia [6A20] [29]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Mesoridazine and Iloperidone. Schizophrenia [6A20] [28]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Mesoridazine and Paliperidone. Schizophrenia [6A20] [28]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Mesoridazine and Molindone. Schizophrenia [6A20] [29]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Mesoridazine and Thiothixene. Schizophrenia [6A20] [29]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Mesoridazine and Amisulpride. Schizophrenia [6A20] [28]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Asenapine. Schizophrenia [6A20] [28]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Mesoridazine and Pimozide. Schizophrenia [6A20] [30]
⏷ Show the Full List of 9 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Mesoridazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Ivosidenib. Acute myeloid leukaemia [2A60] [31]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Mesoridazine and Midostaurin. Acute myeloid leukaemia [2A60] [28]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Mesoridazine and Idarubicin. Acute myeloid leukaemia [2A60] [28]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Mesoridazine and Arn-509. Acute myeloid leukaemia [2A60] [28]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Mesoridazine and Gilteritinib. Acute myeloid leukaemia [2A60] [28]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Mesoridazine and Oliceridine. Acute pain [MG31] [31]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Mesoridazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [32]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Mesoridazine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [32]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Mesoridazine and Memantine. Alzheimer disease [8A20] [29]
Rivastigmine DMG629M Moderate Antagonize the effect of Mesoridazine when combined with Rivastigmine. Alzheimer disease [8A20] [33]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Mesoridazine and Trimethaphan. Aneurysm/dissection [BD50] [34]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Mesoridazine and Ivabradine. Angina pectoris [BA40] [30]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Bepridil. Angina pectoris [BA40] [31]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Dronedarone. Angina pectoris [BA40] [28]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Mesoridazine and Amyl nitrite. Angina pectoris [BA40] [35]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Mesoridazine and Nifedipine. Angina pectoris [BA40] [35]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Mesoridazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [28]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Mesoridazine and Cilostazol. Arterial occlusive disease [BD40] [28]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Mesoridazine and Posaconazole. Aspergillosis [1F20] [28]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Mesoridazine and Levalbuterol. Asthma [CA23] [36]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Mesoridazine and Pirbuterol. Asthma [CA23] [36]
Ephedrine DMMV0KW Moderate Antagonize the effect of Mesoridazine when combined with Ephedrine. Asthma [CA23] [37]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Mesoridazine and Salbutamol. Asthma [CA23] [38]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Mesoridazine and Formoterol. Asthma [CA23] [39]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [28]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Mesoridazine and Desipramine. Attention deficit hyperactivity disorder [6A05] [28]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Ofloxacin. Bacterial infection [1A00-1C4Z] [28]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Mesoridazine and Clarithromycin. Bacterial infection [1A00-1C4Z] [28]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Mesoridazine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [28]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Mesoridazine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [31]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Mesoridazine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [28]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Norfloxacin. Bacterial infection [1A00-1C4Z] [31]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Mesoridazine and Levofloxacin. Bacterial infection [1A00-1C4Z] [28]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Mesoridazine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [31]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Mesoridazine and Telithromycin. Bacterial infection [1A00-1C4Z] [31]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Mesoridazine and Retigabine. Behcet disease [4A62] [31]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Mesoridazine and Cariprazine. Bipolar disorder [6A60] [29]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Mesoridazine and Eribulin. Breast cancer [2C60-2C6Y] [28]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Mesoridazine and Lapatinib. Breast cancer [2C60-2C6Y] [28]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Mesoridazine and Bosutinib. Breast cancer [2C60-2C6Y] [28]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Mesoridazine when combined with Acetylcholine. Cataract [9B10] [40]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Mesoridazine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [31]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Mesoridazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [41]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Mesoridazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [39]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Mesoridazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [36]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Mesoridazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [41]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Mesoridazine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [39]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Mesoridazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [41]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Mesoridazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [39]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Mesoridazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [39]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Mesoridazine and Dihydrocodeine. Chronic pain [MG30] [42]
Isoproterenol DMK7MEY Major Increased risk of prolong QT interval by the combination of Mesoridazine and Isoproterenol. Conduction disorder [BC63] [39]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Halothane. Corneal disease [9A76-9A78] [28]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Sevoflurane. Corneal disease [9A76-9A78] [28]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Mesoridazine and Probucol. Coronary atherosclerosis [BA80] [31]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Mesoridazine and Pasireotide. Cushing syndrome [5A70] [28]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Mesoridazine and Osilodrostat. Cushing syndrome [5A70] [31]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Mesoridazine and Cyclandelate. Dementia [6D80-6D8Z] [34]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Mesoridazine and Sertraline. Depression [6A70-6A7Z] [28]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Mesoridazine and Selegiline. Depression [6A70-6A7Z] [43]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Mesoridazine and Isocarboxazid. Depression [6A70-6A7Z] [43]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Mesoridazine and Escitalopram. Depression [6A70-6A7Z] [28]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Mesoridazine and OPC-34712. Depression [6A70-6A7Z] [29]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Mesoridazine and Clomipramine. Depression [6A70-6A7Z] [28]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Mesoridazine and Doxepin. Depression [6A70-6A7Z] [28]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Mesoridazine and Maprotiline. Depression [6A70-6A7Z] [28]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Mesoridazine and Esketamine. Depression [6A70-6A7Z] [31]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Mesoridazine and Mepenzolate. Digestive system disease [DE2Z] [32]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Mesoridazine and Oxybutynine. Discovery agent [N.A.] [29]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Mesoridazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [28]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Mesoridazine and Deutetrabenazine. Dystonic disorder [8A02] [28]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Mesoridazine and Ingrezza. Dystonic disorder [8A02] [28]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Mesoridazine when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [44]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Mesoridazine and Nadolol. Essential hypertension [BA00] [35]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Mesoridazine and Solifenacin. Functional bladder disorder [GC50] [28]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Mesoridazine and Tolterodine. Functional bladder disorder [GC50] [29]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Mesoridazine and Ketoconazole. Fungal infection [1F29-1F2F] [28]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Mesoridazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [28]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Mesoridazine when combined with Pilocarpine. Glaucoma [9C61] [40]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Mesoridazine and Carvedilol. Heart failure [BD10-BD1Z] [35]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Mesoridazine and Procarbazine. Hodgkin lymphoma [2B30] [43]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Mesoridazine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [31]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Mesoridazine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [28]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [31]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Mesoridazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [28]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Mesoridazine and Isosorbide mononitrate. Hydrocephalus [8D64] [35]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Mesoridazine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [31]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Mesoridazine and Acebutolol. Hypertension [BA00-BA04] [35]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Mesoridazine and Captopril. Hypertension [BA00-BA04] [35]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Mesoridazine and Penbutolol. Hypertension [BA00-BA04] [34]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Mesoridazine and Methyldopa. Hypertension [BA00-BA04] [35]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Mesoridazine and Nebivolol. Hypertension [BA00-BA04] [35]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Mesoridazine and Levamlodipine. Hypertension [BA00-BA04] [35]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Mesoridazine and TAK-491. Hypertension [BA00-BA04] [35]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Mesoridazine and Pindolol. Hypertension [BA00-BA04] [35]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Mesoridazine and Trichlormethiazide. Hypertension [BA00-BA04] [34]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Mesoridazine and Diazoxide. Hypertension [BA00-BA04] [35]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Mesoridazine and Felodipine. Hypertension [BA00-BA04] [35]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Mesoridazine and Deserpidine. Hypertension [BA00-BA04] [34]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Mesoridazine and Telmisartan. Hypertension [BA00-BA04] [35]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Mesoridazine and Irbesartan. Hypertension [BA00-BA04] [35]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Mesoridazine and Hydralazine. Hypertension [BA00-BA04] [35]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of ventricular arrhythmias by the combination of Mesoridazine and Hydrochlorothiazide. Hypertension [BA00-BA04] [31]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Mesoridazine and Clevidipine butyrate. Hypertension [BA00-BA04] [35]
Givosiran DM5PFIJ Moderate Decreased metabolism of Mesoridazine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [45]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Mesoridazine and Belladonna. Infectious gastroenteritis/colitis [1A40] [29]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Mesoridazine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [46]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Mesoridazine and ITI-007. Insomnia [7A00-7A0Z] [29]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Mesoridazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [47]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Mesoridazine and Phenolphthalein. Irritable bowel syndrome [DD91] [31]
Physostigmine DM2N0TO Moderate Antagonize the effect of Mesoridazine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [33]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Mesoridazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [30]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Mesoridazine and Crizotinib. Lung cancer [2C25] [28]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Mesoridazine and Ceritinib. Lung cancer [2C25] [28]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Mesoridazine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [48]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Mesoridazine and Osimertinib. Lung cancer [2C25] [28]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Mesoridazine and Selpercatinib. Lung cancer [2C25] [31]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Mesoridazine and Lumefantrine. Malaria [1F40-1F45] [31]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Mesoridazine and Halofantrine. Malaria [1F40-1F45] [31]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Mesoridazine and Hydroxychloroquine. Malaria [1F40-1F45] [28]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Mesoridazine and Primaquine. Malaria [1F40-1F45] [28]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [28]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [28]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Vemurafenib. Melanoma [2C30] [28]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Mesoridazine and LGX818. Melanoma [2C30] [28]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Mesoridazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [49]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Mesoridazine and Lasmiditan. Migraine [8A80] [50]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Mesoridazine and Flibanserin. Mood disorder [6A60-6E23] [51]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Mesoridazine and Panobinostat. Multiple myeloma [2A83] [28]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Mesoridazine and Thalidomide. Multiple myeloma [2A83] [30]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Mesoridazine and Siponimod. Multiple sclerosis [8A40] [31]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Mesoridazine and Fingolimod. Multiple sclerosis [8A40] [28]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Ozanimod. Multiple sclerosis [8A40] [28]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Mesoridazine and Romidepsin. Mycosis fungoides [2B01] [31]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Mesoridazine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [30]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Mesoridazine and Nilotinib. Myeloproliferative neoplasm [2A20] [28]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Mesoridazine and Dasatinib. Myeloproliferative neoplasm [2A20] [28]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Mesoridazine when combined with Dextroamphetamine. Narcolepsy [7A20] [37]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Mesoridazine and Phenindamine. Nasopharyngitis [CA00] [32]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Mesoridazine and Dimenhydrinate. Nausea/vomiting [MD90] [29]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Mesoridazine and Promethazine. Nausea/vomiting [MD90] [28]
Rolapitant DM8XP26 Moderate Decreased metabolism of Mesoridazine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [52]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Mesoridazine and Cyclizine. Nausea/vomiting [MD90] [32]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Mesoridazine and Metoclopramide. Nausea/vomiting [MD90] [53]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Mesoridazine and Bupropion. Nicotine use disorder [6C4A] [28]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Mesoridazine and Entrectinib. Non-small cell lung cancer [2C25] [31]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Mesoridazine when combined with Phendimetrazine. Obesity [5B80-5B81] [37]
Amfepramone DM9YSNQ Moderate Antagonize the effect of Mesoridazine when combined with Amfepramone. Obesity [5B80-5B81] [37]
Lorcaserin DMG6OYJ Moderate Increased risk of hyperprolactinemic effects by the combination of Mesoridazine and Lorcaserin. Obesity [5B80-5B81] [54]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Mesoridazine and Polythiazide. Oedema [MG29] [31]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Levomethadyl Acetate. Opioid use disorder [6C43] [30]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Lofexidine. Opioid use disorder [6C43] [28]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Mesoridazine and Apraclonidine. Optic nerve disorder [9C40] [55]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Rucaparib. Ovarian cancer [2C73] [28]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Mesoridazine and Oxymorphone. Pain [MG30-MG3Z] [56]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Mesoridazine and Dezocine. Pain [MG30-MG3Z] [42]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Mesoridazine and Flavoxate. Pain [MG30-MG3Z] [29]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Mesoridazine when combined with Methamphetamine. Pain [MG30-MG3Z] [57]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Mesoridazine and Hydrocodone. Pain [MG30-MG3Z] [34]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Mesoridazine and Triclabendazole. Parasitic worm infestation [1F90] [31]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Mesoridazine and Safinamide. Parkinsonism [8A00] [43]
Pergolide DM14MAE Moderate Antagonize the effect of Mesoridazine when combined with Pergolide. Parkinsonism [8A00] [58]
Opicapone DM1BKA6 Moderate Antagonize the effect of Mesoridazine when combined with Opicapone. Parkinsonism [8A00] [59]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Mesoridazine and Rasagiline. Parkinsonism [8A00] [43]
Levodopa DMN3E57 Moderate Antagonize the effect of Mesoridazine when combined with Levodopa. Parkinsonism [8A00] [58]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Mesoridazine and Pimavanserin. Parkinsonism [8A00] [28]
Bromocriptine DMVE3TK Moderate Additive CNS depression effects by the combination of Mesoridazine and Bromocriptine. Parkinsonism [8A00] [58]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Mesoridazine and Orphenadrine. Parkinsonism [8A00] [29]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Mesoridazine and Methylscopolamine. Peptic ulcer [DA61] [29]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Mesoridazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [60]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Lefamulin. Pneumonia [CA40] [31]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Mesoridazine and Degarelix. Prostate cancer [2C82] [28]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Mesoridazine and ABIRATERONE. Prostate cancer [2C82] [28]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Mesoridazine and Enzalutamide. Prostate cancer [2C82] [28]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Mesoridazine and Relugolix. Prostate cancer [2C82] [28]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Mesoridazine and Bicalutamide. Prostate cancer [2C82] [28]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Mesoridazine and Terazosin. Prostate hyperplasia [GA90] [35]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Mesoridazine and Silodosin. Prostate hyperplasia [GA90] [35]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Mesoridazine and Levomepromazine. Psychotic disorder [6A20-6A25] [31]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [31]
Neupro DMHEAB1 Moderate Antagonize the effect of Mesoridazine when combined with Neupro. Restless legs syndrome [7A80] [58]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Mesoridazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [28]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Mesoridazine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [28]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Mesoridazine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [28]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Mesoridazine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [28]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Mesoridazine and Pitolisant. Somnolence [MG42] [28]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Mesoridazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [28]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Lenvatinib. Thyroid cancer [2D10] [28]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Cabozantinib. Thyroid cancer [2D10] [28]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Mesoridazine and Papaverine. Tonus and reflex abnormality [MB47] [61]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Mesoridazine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [29]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Mesoridazine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [31]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Mesoridazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [32]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Procainamide. Ventricular tachyarrhythmia [BC71] [28]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Mesoridazine and Propafenone. Ventricular tachyarrhythmia [BC71] [28]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Mesoridazine and Flecainide. Ventricular tachyarrhythmia [BC71] [28]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Mesoridazine and Amiodarone. Ventricular tachyarrhythmia [BC71] [28]
⏷ Show the Full List of 197 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7227).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016774.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as... J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87.
7 Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
8 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
9 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
10 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
11 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
14 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
15 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
16 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
17 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
18 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
19 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
20 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
21 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
22 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
24 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
25 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
26 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
27 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
28 Canadian Pharmacists Association.
29 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
30 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
31 Cerner Multum, Inc. "Australian Product Information.".
32 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
33 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
34 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
35 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
36 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
37 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
38 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
39 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
40 Multum Information Services, Inc. Expert Review Panel.
41 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
42 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
43 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
44 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
45 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
46 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
47 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
48 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
49 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
50 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
51 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
52 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
53 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
54 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
55 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
56 Cerner Multum, Inc. "Canadian Product Information.".
57 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
58 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
59 Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
60 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
61 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]